Published in Clin J Am Soc Nephrol on March 04, 2009
The hazards of hazard ratios. Epidemiology (2010) 5.24
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int (2011) 1.56
Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol (2013) 1.06
Estimating the effects of multiple time-varying exposures using joint marginal structural models: alcohol consumption, injection drug use, and HIV acquisition. Epidemiology (2012) 0.89
Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care (2014) 0.87
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol (2016) 0.86
Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol (2009) 0.85
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol (2013) 0.80
Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol (2015) 0.79
Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality? Health Serv Res (2012) 0.78
Exploration of lagged associations using longitudinal data. Biometrics (2013) 0.78
Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. J Clin Epidemiol (2013) 0.77
Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol (2016) 0.77
Individualizing anaemia therapy. NDT Plus (2010) 0.75
Pediatric patients with renal disease and cardiovascular complications: A literature review. ARYA Atheroscler (2014) 0.75
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55
A structural approach to selection bias. Epidemiology (2004) 16.44
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 11.58
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med (2002) 4.15
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol (2003) 2.53
Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis (2008) 2.43
The effect of epoetin dose on hematocrit. Kidney Int (2007) 2.31
Haemoglobin targets: we were wrong, time to move on. Lancet (2007) 2.26
Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol (1999) 2.04
Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis (2004) 2.01
Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol (2001) 1.84
Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol (1997) 1.21
Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens (2001) 1.09
Disparity in outcomes for adult Native American hemodialysis patients? Findings from the ESRD Clinical Performance Measures Project, 1996 to 1999. Kidney Int (2004) 0.95
Severity of AIDS and the response to EPO in uremia. Am J Kidney Dis (1997) 0.90
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The birth weight "paradox" uncovered? Am J Epidemiol (2006) 4.38
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Epidemiology, data sharing, and the challenge of scientific replication. Epidemiology (2009) 3.49
Gout and risk of Parkinson disease: a prospective study. Neurology (2007) 3.09
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med (2004) 2.87
Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology (2008) 2.60
Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology (2008) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol (2009) 2.48
Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it. Int J Epidemiol (2014) 2.23
Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology (2013) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol (2017) 2.05
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis (2004) 2.01
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
We are number one but nobody cares-that's good. Epidemiology (2012) 1.97
A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials (2011) 1.91
Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf (2011) 1.85
Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol (2012) 1.76
Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci (2011) 1.73
Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS (2012) 1.71
Causal inference from longitudinal studies with baseline randomization. Int J Biostat (2008) 1.69
Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology (2010) 1.64
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
Randomized trials analyzed as observational studies. Ann Intern Med (2013) 1.60
Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology (2003) 1.57
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int (2011) 1.56
Impact factor: a call to reason. Epidemiology (2009) 1.54
Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res (2011) 1.49
Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol (2002) 1.46
Antibiotic use and risk of multiple sclerosis. Am J Epidemiol (2006) 1.45
Weight loss in Parkinson's disease. Ann Neurol (2003) 1.43
Weight Loss and Coronary Heart Disease: Sensitivity Analysis for Unmeasured Confounding by Undiagnosed Disease. Epidemiology (2016) 1.39
Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. Epidemiology (2017) 1.38
Causal inference in public health. Annu Rev Public Health (2013) 1.38
Prednisone, lupus activity, and permanent organ damage. J Rheumatol (2009) 1.38
Early versus deferred antiretroviral therapy for HIV. N Engl J Med (2009) 1.35
From causal diagrams to birth weight-specific curves of infant mortality. Eur J Epidemiol (2008) 1.30
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol (2016) 1.29
Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol (2005) 1.27
Invited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes. Am J Epidemiol (2013) 1.27
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis (2012) 1.25
Hypothetical midlife interventions in women and risk of type 2 diabetes. Epidemiology (2013) 1.23
Body mass index, diabetes, and mortality in French women: explaining away a "paradox". Epidemiology (2014) 1.22
Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2010) 1.22
Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol (2003) 1.19
The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Serv Res (2010) 1.18
Effect modification by time-varying covariates. Am J Epidemiol (2007) 1.16
Case-only gene-environment interaction studies: when does association imply mechanistic interaction? Genet Epidemiol (2010) 1.15
Relation between three classes of structural models for the effect of a time-varying exposure on survival. Lifetime Data Anal (2009) 1.14
Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care (2012) 1.12
Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol (2013) 1.12
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (2012) 1.11
Pregnancy outcomes, site of delivery, and community schisms in regions affected by the armed conflict in Chiapas, Mexico. Soc Sci Med (2005) 1.11
Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord (2006) 1.11
Obesity and the risk of Parkinson's disease. Am J Epidemiol (2004) 1.09
Counterpoint: Epidemiology to Guide Decision-Making: Moving Away From Practice-Free Research. Am J Epidemiol (2015) 1.08
Matched designs and causal diagrams. Int J Epidemiol (2013) 1.08
Changes in fish consumption in midlife and the risk of coronary heart disease in men and women. Am J Epidemiol (2013) 1.08
Does dose matter? Nephrol Dial Transplant (2004) 1.07
Selecting on treatment: a pervasive form of bias in instrumental variable analyses. Am J Epidemiol (2015) 1.07
Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis--a prospective cohort study. Neuroepidemiology (2006) 1.06
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol (2004) 1.05
Detection of pulmonary tuberculosis in Chiapas, Mexico. Ann Epidemiol (2002) 1.02
Perinatal factors and adult-onset lupus. Arthritis Rheum (2008) 1.01
Invited commentary: Agent-based models for causal inference—reweighting data and theory in epidemiology. Am J Epidemiol (2014) 1.00
Incidence of adult-onset asthma after hypothetical interventions on body mass index and physical activity: an application of the parametric g-formula. Am J Epidemiol (2013) 1.00
From counterfactuals to sufficient component causes and vice versa. Eur J Epidemiol (2006) 1.00
Ischemic steal syndrome following arm arteriovenous fistula for hemodialysis. Vasc Med (2009) 1.00
Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol (2003) 0.98
Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology (2006) 0.97
Folate intake and risk of Parkinson's disease. Am J Epidemiol (2004) 0.95
β-Blocker use for patients with or at risk for coronary artery disease. JAMA (2013) 0.93
Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. BMC Neurol (2010) 0.93
Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. Clin Infect Dis (2013) 0.92
Ensemble learning of inverse probability weights for marginal structural modeling in large observational datasets. Stat Med (2014) 0.92
Improved survival with higher hematocrits: where is the evidence? Semin Dial (2004) 0.91
Beyond exchangeability: the other conditions for causal inference in medical research. Stat Methods Med Res (2012) 0.90
Think globally, act globally: An epidemiologist's perspective on instrumental variable estimation. Stat Sci (2014) 0.90